Conba Pharmaceutical to reduce registered capital after share cancellation

Zhejiang Conba Pharmaceutical Co., Ltd. announced a reduction in its registered capital from CNY 2,570,037,319 to CNY 2,506,458,271, following the cancellation of repurchased shares. This change was approved by the company's eleventh board of directors at its eleventh (extraordinary) meeting on October 27, 2025, and by the first extraordinary general meeting of shareholders on November 13, 2025.

The reduction decreases the total number of shares by 63,579,048, primarily affecting unrestricted shares. Unrestricted shares will decrease from 2,563,295,466 to 2,499,716,418, while restricted shares remain unchanged at 6,741,853. The proportional ownership of unrestricted shares will slightly decrease from 99.74% to 99.73%, and restricted shares will increase from 0.26% to 0.27% of the total.

Creditors are invited to declare their claims within 30 days of receiving the company's notification or 45 days from the announcement's disclosure date, from November 29, 2025, to January 12, 2026. Claims can be submitted via mail or in person at the company's offices in Hangzhou.